本帖最后由 老马 于 2012-1-13 21:20 编辑 9 S, B* X/ {' j3 {8 a% ^
! `8 @/ t! G# N, v
爱必妥和阿瓦斯丁的比较
2 H% W: l8 a: I+ t4 A9 D, ^& I4 M& S
4 i' K$ K: @; _+ r- }3 whttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/7 _! o U. Q" e" \
1 p2 i! V H3 j6 v
3 o7 G9 A6 I' c4 P. v- f1 x
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
1 {4 R4 V7 x4 U" y+ u1 A==================================================0 H5 k* q, \- \: J
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
0 q/ u2 n$ \. X/ f+ A9 jPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.4 G: o8 `/ _6 y: Q: M# \3 i
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.* I8 W) }' o8 j& u; M$ M T5 Y! e
|